CA2066204A1 - Cystic fibrosis gene - Google Patents
Cystic fibrosis geneInfo
- Publication number
- CA2066204A1 CA2066204A1 CA002066204A CA2066204A CA2066204A1 CA 2066204 A1 CA2066204 A1 CA 2066204A1 CA 002066204 A CA002066204 A CA 002066204A CA 2066204 A CA2066204 A CA 2066204A CA 2066204 A1 CA2066204 A1 CA 2066204A1
- Authority
- CA
- Canada
- Prior art keywords
- cystic fibrosis
- gene
- protein
- fibrosis gene
- diagnosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4712—Cystic fibrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Abstract
The cystic fibrosis gene and its gene product are described for both the normal and mutant forms. The genetic and protein information is used in developing DNA diagnosis, protein diagnosis, carrier and patient screening, drug and gene therapy, cloning of the gene and manufacture of the protein, and development of cystic fibrosis affected animals.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39689489A | 1989-08-22 | 1989-08-22 | |
US39994589A | 1989-08-24 | 1989-08-24 | |
US40160989A | 1989-08-31 | 1989-08-31 | |
US396,894 | 1989-08-31 | ||
US399,945 | 1989-08-31 | ||
US401,609 | 1989-08-31 | ||
PCT/CA1990/000267 WO1991002796A1 (en) | 1989-08-22 | 1990-08-20 | Cystic fibrosis gene |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2066204A1 true CA2066204A1 (en) | 1991-02-23 |
CA2066204C CA2066204C (en) | 2009-03-31 |
Family
ID=27410233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002066204A Expired - Lifetime CA2066204C (en) | 1989-08-22 | 1990-08-20 | Cystic fibrosis gene |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP0489058B1 (en) |
JP (3) | JPH05500306A (en) |
AT (1) | ATE253633T1 (en) |
CA (1) | CA2066204C (en) |
DE (1) | DE69034115T2 (en) |
DK (1) | DK0489058T3 (en) |
ES (1) | ES2210224T3 (en) |
IE (2) | IE903024A1 (en) |
WO (1) | WO1991002796A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7280861B2 (en) | 2000-06-08 | 2007-10-09 | Fralex Therapeutics, Inc. | Diagnosis and classification of disease and disability using low frequency magnetic field designed pulses (Cnps) |
US8871503B2 (en) | 2006-03-28 | 2014-10-28 | Isis Innovation Limited | Construct |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6063913A (en) * | 1989-08-22 | 2000-05-16 | Hsc Research And Development Limited Partnership | Stable heterologous propagation CFTR protein variant cDNA |
US6984487B1 (en) | 1989-08-22 | 2006-01-10 | Hsc Research Development Corporation | Cystic fibrosis gene |
US5240846A (en) * | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
US5543399A (en) * | 1989-08-22 | 1996-08-06 | Hsc Research & Development Limited Partnership | Cystic fibrosis transmembrane conductance regulator (CFTR) protein |
AU7060591A (en) * | 1990-01-12 | 1991-08-05 | Hsc Research Development Corporation | Introns and exons of the cystic fibrosis gene and mutations at various positions of the gene |
US20020164782A1 (en) | 1999-02-10 | 2002-11-07 | Gregory Richard J. | Adenovirus vectors for gene therapy |
US5674898A (en) * | 1990-03-05 | 1997-10-07 | Genzyme Corporation | Methods and therapeutic compositions for treating cystic fibrosis |
US5670488A (en) * | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
CA2037478A1 (en) * | 1990-03-05 | 1991-09-06 | Richard Gregory | Diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator |
US7118911B1 (en) * | 1990-03-05 | 2006-10-10 | Genzyme Corporation | DNA molecules stabilized for propagation in bacterial cells that encode cystic fibrosis transmembrane conductance regulator |
US5981714A (en) * | 1990-03-05 | 1999-11-09 | Genzyme Corporation | Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor |
US5939536A (en) * | 1990-03-05 | 1999-08-17 | Genzyme Corporation | Methods for purifying cystic fibrosis transmembrane conductance regulation |
JPH06510036A (en) * | 1991-08-16 | 1994-11-10 | バイカル・インコーポレイテッド | Compositions and methods for the treatment of cystic fibrosis |
US6013638A (en) * | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
US6627615B1 (en) | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
AU3467193A (en) * | 1991-12-17 | 1993-07-19 | Regents Of The University Of California, The | Gene therapy for cystic fibrosis transmembrane conductance regulator activity (CFTR) |
US6806084B1 (en) | 1992-06-04 | 2004-10-19 | The Regents Of The University Of California | Methods for compositions for in vivo gene delivery |
CA2134773A1 (en) * | 1992-06-04 | 1993-12-09 | Robert J. Debs | Methods and compositions for in vivo gene therapy |
GB9217885D0 (en) * | 1992-08-21 | 1992-10-07 | Medical Res Council | Mutant mice |
FR2700011B1 (en) * | 1992-12-24 | 1995-02-24 | Inst Nat Sante Rech Med | Detection of cystic fibrosis or a mutation in the CFTR gene by means of a PAP assay. |
US5582825A (en) * | 1993-02-24 | 1996-12-10 | Gunze Limited | Therapeutic medicine for cystic fibrosis |
WO1995007453A1 (en) * | 1993-09-08 | 1995-03-16 | Genzyme Corporation | A method for purifying a membrane-associated protein |
US5688677A (en) * | 1993-10-13 | 1997-11-18 | Genzyme Corporation | Deoxyribonucleic acids containing inactivated hormone responsive elements |
US5639661A (en) * | 1994-03-23 | 1997-06-17 | The University Of Iowa Research Foundation | Genes and proteins for treating cystic fibrosis |
US6344445B1 (en) | 1995-10-19 | 2002-02-05 | Cantab Pharmaceutical Research Limited | Herpes virus vectors and their uses |
US6245735B1 (en) | 1996-07-29 | 2001-06-12 | The Brigham And Women's Hospital, Inc. | Methods and products for treating pseudomonas infection |
US6258533B1 (en) | 1996-11-01 | 2001-07-10 | The University Of Iowa Research Foundation | Iterative and regenerative DNA sequencing method |
US5858671A (en) * | 1996-11-01 | 1999-01-12 | The University Of Iowa Research Foundation | Iterative and regenerative DNA sequencing method |
NZ527899A (en) * | 1997-12-03 | 2004-10-29 | Genentech Inc | Polypeptides and nucleic acids with homology to acid-labile subunit of insulin-like growth factor |
EP1191101B1 (en) * | 1997-12-11 | 2004-06-09 | Genentech, Inc. | PRO241 polypeptides and nucleic acid encoding the same |
US7119172B2 (en) | 2001-05-21 | 2006-10-10 | The Brigham And Women's Hospital, Inc. | P. aeruginosa mucoid exopolysaccharide specific binding peptides |
US6962813B2 (en) | 2001-05-21 | 2005-11-08 | The Brigham And Women's Hospital, Inc. | P. aeruginosa mucoid exopolysaccharide specific binding peptides |
EP1655608A1 (en) * | 2004-11-04 | 2006-05-10 | Inserm | CFTR as a component of an autophagy signaling pathway, applications thereof to autophagic diseases, and determination of cystic fibrosis as an autophagic disease |
WO2011119531A1 (en) | 2010-03-22 | 2011-09-29 | Esoterix Genetic Laboratories, Llc | Mutations associated with cystic fibrosis |
WO2013181446A2 (en) | 2012-05-30 | 2013-12-05 | University Of Medicine And Dentistry Of New Jersey | Metabolic therapy for oxidative stress in the brain through targeted neuronal catabolism of n-acetyl-aspartic acid |
EP3921334A1 (en) * | 2019-02-08 | 2021-12-15 | Krystal Biotech, Inc. | Compositions and methods for delivering cftr polypeptides |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8709652D0 (en) * | 1987-04-23 | 1987-05-28 | Williamson R | Diagnosis of cystic fibrosis |
CA2037478A1 (en) * | 1990-03-05 | 1991-09-06 | Richard Gregory | Diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator |
-
1990
- 1990-08-20 ES ES90912428T patent/ES2210224T3/en not_active Expired - Lifetime
- 1990-08-20 EP EP90912428A patent/EP0489058B1/en not_active Expired - Lifetime
- 1990-08-20 CA CA002066204A patent/CA2066204C/en not_active Expired - Lifetime
- 1990-08-20 DK DK90912428T patent/DK0489058T3/en active
- 1990-08-20 JP JP2511424A patent/JPH05500306A/en active Pending
- 1990-08-20 AT AT90912428T patent/ATE253633T1/en not_active IP Right Cessation
- 1990-08-20 DE DE69034115T patent/DE69034115T2/en not_active Expired - Lifetime
- 1990-08-20 EP EP03078489A patent/EP1418183A1/en not_active Withdrawn
- 1990-08-20 WO PCT/CA1990/000267 patent/WO1991002796A1/en active IP Right Grant
- 1990-08-21 IE IE302490A patent/IE903024A1/en not_active IP Right Cessation
- 1990-08-21 IE IE20040698A patent/IE20040698A1/en not_active Application Discontinuation
-
2001
- 2001-11-29 JP JP2001402257A patent/JP2002355088A/en not_active Withdrawn
-
2004
- 2004-02-05 JP JP2004029998A patent/JP2004208694A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7280861B2 (en) | 2000-06-08 | 2007-10-09 | Fralex Therapeutics, Inc. | Diagnosis and classification of disease and disability using low frequency magnetic field designed pulses (Cnps) |
US8871503B2 (en) | 2006-03-28 | 2014-10-28 | Isis Innovation Limited | Construct |
US11214815B2 (en) | 2006-03-28 | 2022-01-04 | Ip2Ipo Innovations Limited | Nucleic acid Construct |
Also Published As
Publication number | Publication date |
---|---|
DE69034115T2 (en) | 2004-07-15 |
EP1418183A1 (en) | 2004-05-12 |
WO1991002796A1 (en) | 1991-03-07 |
IE20040698A1 (en) | 2004-12-01 |
JPH05500306A (en) | 1993-01-28 |
EP0489058B1 (en) | 2003-11-05 |
ATE253633T1 (en) | 2003-11-15 |
JP2004208694A (en) | 2004-07-29 |
AU647408B2 (en) | 1994-03-24 |
AU6161690A (en) | 1991-04-03 |
ES2210224T3 (en) | 2004-07-01 |
DK0489058T3 (en) | 2004-03-22 |
EP0489058A1 (en) | 1992-06-10 |
CA2066204C (en) | 2009-03-31 |
JP2002355088A (en) | 2002-12-10 |
IE903024A1 (en) | 1991-02-27 |
DE69034115D1 (en) | 2003-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2066204A1 (en) | Cystic fibrosis gene | |
AU1250695A (en) | Promoter | |
FR2731014B1 (en) | DNA MOLECULES, PREPARATION AND USE IN GENE THERAPY | |
CA2071214A1 (en) | Method of delivering molecules into eukaryotic cells | |
NZ335945A (en) | Presenilin proteins and genetic sequences that are related to Alzheimer's disease | |
NO903542D0 (en) | FREEZE-DRY MIXED AND PROCEDURE FOR ORAL ADMINISTRATION OF PHARMACEUTICALS, FOODSTUFFS AND BIOLOGICAL ACTIVE MATERIALS. | |
NO165194C (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE N-SUBSTITUTED-N- (3- (1,2,4-TRIAZOLO (4,3-6) PYRIDAZIN-6-YL) -PHENYL) ALKANAMIDES, CARBAMATES AND URINES. | |
GR970300021T1 (en) | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof | |
MY102472A (en) | Preparation of funtional human urokinase proteins. | |
EP0259160A3 (en) | Synthetic genes for human interleukin 1-alpha | |
OA09116A (en) | Novel protein, sequences containing the gene therefore vectors, methods of preparation and use. | |
NZ237198A (en) | Zymogen form of protein c, dna, vector and use as a pharmaceutical | |
AU3069584A (en) | Peptides, pharmaceutical compositions,genes,vectors,host organisms, processes for there production and diagnostic reagents | |
AU3204689A (en) | Amyloid protein precursors, genetic probes, antibodies, and methods of use | |
EP0853486A3 (en) | Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases | |
EP0744408A3 (en) | Rhesus ob protein and DNA | |
CA2199832A1 (en) | Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease | |
JPS6430588A (en) | Foreign dna developing promoter n methylotroph bacteria, its production and use | |
CA2066263A1 (en) | Tsh receptor | |
CA2032167A1 (en) | Dna coding for protein binds to enhancer of.alpha.-fetoprotein gene | |
EP0567785A3 (en) | Protein having alpha-glucosidase activity, DNA having genetic information thereof, and production of alpha-glucosidase. | |
CA2215745A1 (en) | Human stat4 | |
AU1867297A (en) | Gene-therapeutic nucleic acid construct, production of same and use of same in the treatment of heart disorders | |
AU6401696A (en) | Early onset alzheimer's disease gene and gene products | |
AU6822796A (en) | T-pa polymorphism and use thereof in diagnosis of risk of thrombus associated disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |